Last reviewed · How we verify

Aspirin 100mg

Azienda Ospedaliero Universitaria Maggiore della Carita · FDA-approved active Small molecule Quality 2/100

Aspirin 100mg, marketed by Azienda Ospedaliero Universitaria Maggiore della Carita, holds a well-established position in the pharmaceutical market. The key composition patent for Aspirin 100mg is set to expire in 2028, which may present a significant competitive advantage until then. The primary risk is the potential increase in generic competition following the patent expiry in 2028.

At a glance

Generic nameAspirin 100mg
Also known asAspirin protect, Aspirin enteric coated, Aspirin, Oxygen therapy, antiviral treatment and other support treatments
SponsorAzienda Ospedaliero Universitaria Maggiore della Carita
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: